New CVS deal highlights value in AET bonds
admin | August 14, 2020
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors.
CVS tapped the debt market for the second time this year with proceeds, coupled with cash on hand, used to fund a tender offer of some its 2023 and 2025 bonds. The issuance and tender help to smooth out two of its three largest debt maturity years while extending duration. Given the overall rate environment and that spreads are only +20 bp off the tights witnessed in February, CVS was able to price the deal at record low coupons for its capital structure. CVS priced a new 20-year bond (2.7% 8/21/40) at +135 bp (+157 bp g-spread) and is currently trading right around new issue level. A comparative value are the bonds of CVS’ wholly owned operating subsidiary, AET 6.625% 6/15/36, which are currently trading at the +163 bp level (+205 bp g-spread). A swap out of the new CVS 20-year bond into the AET 2036 bonds provides for a pickup of +47 bp g-spread while shortening maturity by 4 years.
Exhibit 1: CVS curve 5-year to 30-year
Source: Bloomberg TRACE
AET Outperforms in 2Q
Second quarter results saw a large benefit from the Healthcare Benefits unit which more than offset higher operating costs associated with increased pay wages and cleaning costs at the retail unit. Revenues at the Healthcare Benefits unit were up 6.1% driven by strong membership growth in Medicare and Medicaid products. Government membership was up 22.4% year-over-year to $6.1 million. Adjusted operating income witnessed at strong 141% increase year-over-year to $3.5 billion, primarily driven by unprecedented lower benefit costs due to the deferral of discretionary medical visits as quarantine orders called for a shelter-in-place. As such, the medical benefit ratio (the lower the better for profitability) declined 1370 bp year-over-year to 70.3%. This growth is expected to moderate in 2H20 as shelter in place orders have largely been lifted.
Liquidity Strong and Cash Flow Supports Debt Reduction
CVS ended the quarter with total liquidity of roughly $13 billion as cash and equivalents totaled $7 billion and the company had $6 billion of availability under its credit facilities. During the quarter, CVS generated a very strong $6.7 billion in free cash flow, which was up from $4.8 billion in the year ago period. Management continues to prioritize debt reduction and repaid $2.75 billion of debt that matured in July (subsequent to quarter end). Management also reiterated its commitment to not repurchasing shares until it achieves its leverage target of low 3.0x, which they noted they remain on track to hit in 2022. At quarter end, we estimate that debt/EBITDA was 3.7x, while lease adjusted leverage was a half turn higher at 4.2x. Post the aforementioned debt reduction, leverage has declined another two ticks to 3.5x and 4.0x, respectively. CVS met S&P’s deleveraging expectation in fiscal 2019 and the agency believes that the deleveraging trend will continue given the company’s ample free cash flow generation.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Copyright © 2023 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.